Search company, investor...

EKR Therapeutics

Founded Year



Acquired | Acquired

Total Raised


About EKR Therapeutics

EKR Therapeutics is a specialty pharmaceutical company committed to serving the acute-care hospital setting by identifying, commercializing, and marketing products to address unmet or undersatisfied medical needs. The company's product offerings include Ready-to-Use CARDENE I.V. (nicardipine hydrochloride), DepoDur (morphine sulfate extended-release liposome injection), and Retavase (reteplase, recombinant).

Headquarters Location

1545 US Highway 206 Third Floor

Bedminster, New Jersey, 07921,

United States


Missing: EKR Therapeutics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: EKR Therapeutics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing EKR Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

EKR Therapeutics is included in 1 Expert Collection, including Diabetes.



1,903 items

EKR Therapeutics Patents

EKR Therapeutics has filed 10 patents.

The 3 most popular patent topics include:

  • Amines
  • Calcium channel blockers
  • Enantiopure drugs
patents chart

Application Date

Grant Date


Related Topics




Calcium channel blockers, Glycine receptor antagonists, Carboxylate esters, Glycine receptor agonists, Lactams


Application Date


Grant Date



Related Topics

Calcium channel blockers, Glycine receptor antagonists, Carboxylate esters, Glycine receptor agonists, Lactams



Latest EKR Therapeutics News

EKR Therapeutics Inc. Mergers Acquisitions MA Partnerships Alliances and Investment Report Prices from USD $350

Nov 28, 2016

EKR Therapeutics, Inc. Mergers Acquisitions MA, Partnerships Alliances and Investment Report Prices from USD $350 21:46 EST 27 Nov 2016 | BioPortfolio Reports Home » Topics » Biotechnology Business » Latest News » EKR Therapeutics, Inc. Mergers Acquisitions MA, Partnerships Alliances and Investment Report Prices from USD $350 Summary MarketLine's Company Mergers Acquisitions MA, Partnerships Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' EKR Therapeutics, Inc. Mergers Acquisitions MA, Partnerships Alliances and Investments report includes business description, detailed reports on mergers and acquisitions MA, divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by EKR Therapeutics, Inc. since January 2007. Key Findings Provides intelligence on EKR Therapeutics, Inc. MA, strategic partnerships and alliances, capital raising and private equity transactions. Detailed reports of various financial transactions undertaken by EKR Therapeutics, Inc. and its subsidiaries since 2007. Information about key financial and legal advisors for EKR Therapeutics, Inc.'s financial deals transactions. Financial deals tables and charts covering deal value and volumes trend, deal types and geographybased deal activity. ReasonsToBuy Access comprehensive financial deals data along with charts and graph covering MA, private equity, and partnerships and alliances. Form an independent opinion about EKR Therapeutics, Inc.'s growth strategies through the organic and inorganic activities undertaken since 2007. Track your competitors' business structure and growth strategies. Related Biotechnology, Pharmaceutical and Healthcare News

EKR Therapeutics Frequently Asked Questions (FAQ)

  • When was EKR Therapeutics founded?

    EKR Therapeutics was founded in 2006.

  • Where is EKR Therapeutics's headquarters?

    EKR Therapeutics's headquarters is located at 1545 US Highway 206, Bedminster.

  • What is EKR Therapeutics's latest funding round?

    EKR Therapeutics's latest funding round is Acquired.

  • How much did EKR Therapeutics raise?

    EKR Therapeutics raised a total of $160M.

  • Who are the investors of EKR Therapeutics?

    Investors of EKR Therapeutics include Cornerstone Therapeutics, ESP Equity Partners, NewSpring Capital, Quaker BioVentures, LLR Partners and 6 more.

  • Who are EKR Therapeutics's competitors?

    Competitors of EKR Therapeutics include REGENESIS BIOMEDICAL, Acelity, Abaxis, Keystone Dental, Celleration and 13 more.

Compare EKR Therapeutics to Competitors

KT Tape

2nd place finisher at the 2009 BYU Business Plan Competition. KT Tape brings kinesiology therapeutic tape directly to the consumers. The tape has the same elasticity as skin and relieves pain by lifting skin off of the injured location to increase circulation. KT Tape already has an exclusive endorsement from Kerri Walsh -- U.S. Olympic volleyball player who wore the tape at the Beijing Olympics


Zeno Corporation is a Houston-based medical technology company engaged in the development of products using its patented ClearPoint technologyˆ as well as other products related to skin care.


Aksys has developed an automated personal hemodialysis system for patient-performed hemodialysis in alternative care settings such as the patient's home.

Emergent Respiratory Products

Emergent Respiratory Products, Inc., located in Irvine, CA, aims to develop, manufacture and market a medical device for delivering non-invasive ventilation therapy. Emergent's products can be utilized in a range of care settings, including emergency medical service (EMS) transport to the hospital and alternative site/home care settings.

Daverci Solutions

Daverci Solutions aims to make electronic medication management systems for long-term care facilities and the institutional pharmacies that supply them.

Acacian Emergency Solutions

Acacian Emergency Solutions is developing a system that permits emergency medical personnel in ambulances to wirelessly transmit critical patient data to hospital emergency rooms in real time using existing cellular networks. This system substantially aims to improve patient care as the actions within a few minutes of an emergency can seriously affect a patient's future.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.